Cue Biopharma Stock Performance
| CUE Stock | USD 1.09 0.03 2.83% |
Cue Biopharma holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 1.13, which signifies a somewhat significant risk relative to the market. Cue Biopharma returns are very sensitive to returns on the market. As the market goes up or down, Cue Biopharma is expected to follow. Use Cue Biopharma potential upside, rate of daily change, and the relationship between the sortino ratio and skewness , to analyze future returns on Cue Biopharma.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cue Biopharma are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Cue Biopharma exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Acquisition by Lucinda Warren of 350000 shares of Cue Biopharma at 0.66 subject to Rule 16b-3 | 09/03/2024 |
2 | SP 500 lifts as Wall St seeks stability amid September turbulence | 09/10/2024 |
3 | Cue Biopharma prices 12M stock offering | 09/27/2024 |
4 | Cue Biopharma stock rallies nearly 40 percent on upcoming presentations | 10/04/2024 |
5 | Acquisition by Sandercock Colin of 100000 shares of Cue Biopharma at 3.21 subject to Rule 16b-3 | 10/09/2024 |
6 | Cue BiopharmaPresents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC th Annua... | 11/08/2024 |
7 | Cue BiopharmaAnnounces Strategic Organizational Transition | 11/14/2024 |
8 | Acquisition by Howson Tamar D of 10000 shares of Cue Biopharma subject to Rule 16b-3 | 11/25/2024 |
| Begin Period Cash Flow | 51.8 M |
Cue |
Cue Biopharma Relative Risk vs. Return Landscape
If you would invest 72.00 in Cue Biopharma on August 29, 2024 and sell it today you would earn a total of 37.00 from holding Cue Biopharma or generate 51.39% return on investment over 90 days. Cue Biopharma is generating 1.2688% of daily returns assuming volatility of 12.0159% on return distribution over 90 days investment horizon. In other words, majority of equities are less volatile than Cue, and most equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Cue Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cue Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cue Biopharma, and traders can use it to determine the average amount a Cue Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1056
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | CUE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.02 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.27 actual daily | 25 75% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Cue Biopharma is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cue Biopharma by adding it to a well-diversified portfolio.
Cue Biopharma Fundamentals Growth
Cue Stock prices reflect investors' perceptions of the future prospects and financial health of Cue Biopharma, and Cue Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cue Stock performance.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.52 | ||||
| Operating Margin | (3.91) % | ||||
| Current Valuation | 44.24 M | ||||
| Shares Outstanding | 63.35 M | ||||
| Price To Earning | (2.17) X | ||||
| Price To Book | 2.55 X | ||||
| Price To Sales | 8.10 X | ||||
| Revenue | 5.49 M | ||||
| Gross Profit | 1.25 M | ||||
| EBITDA | (46.05 M) | ||||
| Net Income | (50.73 M) | ||||
| Cash And Equivalents | 66.13 M | ||||
| Cash Per Share | 1.87 X | ||||
| Total Debt | 14.7 M | ||||
| Debt To Equity | 0.33 % | ||||
| Current Ratio | 8.29 X | ||||
| Book Value Per Share | 0.79 X | ||||
| Cash Flow From Operations | (39.96 M) | ||||
| Earnings Per Share | (0.91) X | ||||
| Market Capitalization | 67.15 M | ||||
| Total Asset | 61.53 M | ||||
| Retained Earnings | (301.19 M) | ||||
| Working Capital | 34.37 M | ||||
| Current Asset | 42.21 M | ||||
| Current Liabilities | 3.38 M | ||||
About Cue Biopharma Performance
By analyzing Cue Biopharma's fundamental ratios, stakeholders can gain valuable insights into Cue Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cue Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cue Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.82) | (0.87) | |
| Return On Capital Employed | (1.17) | (1.23) | |
| Return On Assets | (0.82) | (0.87) | |
| Return On Equity | (1.37) | (1.44) |
Things to note about Cue Biopharma performance evaluation
Checking the ongoing alerts about Cue Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cue Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cue Biopharma is way too risky over 90 days horizon | |
| Cue Biopharma has some characteristics of a very speculative penny stock | |
| Cue Biopharma appears to be risky and price may revert if volatility continues | |
| Cue Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 5.49 M. Reported Net Loss for the year was (50.73 M) with profit before taxes, overhead, and interest of 1.25 M. | |
| Cue Biopharma has about 66.13 M in cash with (39.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.87, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cue Biopharma has a frail financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Acquisition by Howson Tamar D of 10000 shares of Cue Biopharma subject to Rule 16b-3 |
- Analyzing Cue Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cue Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Cue Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cue Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cue Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cue Biopharma's stock. These opinions can provide insight into Cue Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cue Stock analysis
When running Cue Biopharma's price analysis, check to measure Cue Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cue Biopharma is operating at the current time. Most of Cue Biopharma's value examination focuses on studying past and present price action to predict the probability of Cue Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cue Biopharma's price. Additionally, you may evaluate how the addition of Cue Biopharma to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |